[ad_1]
Israeli scientists from Accelerated Evolution Biotechnologies LTD., Recently announced that they thought they had discovered a universal cancer treatment that works with a single injection and does not require toxic chemotherapy, nor radiotherapy, nor surgery. and they come under surveillance.
"Our anti-cancer drug is effective from the first day and lasts a few weeks. Its side effects are nil or minimal and its cost is much lower than most other treatments available on the market. We think we will propose it in a year. a complete cure for cancer " The principal investigator, Dan Aridor, told the Jerusalem Post.
MuTaTo is a multi-target compound that functions essentially as an antibiotic. His results are very promising in preclinical trials. They are trying to advance their research as quickly as possible for clinical trials. Exploratory experiments on mice inhibited the growth of human cancer cells, having no effect on healthy mouse cells, in addition to several in vitro badays, with consistent and reproducible results, according to the Jerusalem Post.
MuTaTo aims to target cancer stem cells to eliminate the risk of recurrence. It is suggested that their solution be generic and personal using a multi-pronged approach similar to the treatment given to HIV patients, using a combination of several peptides for each cancer cell to eliminate the risks of mutation escape.
Based on SoAP technology, MuTaTo involves the introduction of a DNA encoding a protein into a bacteriophage, which is then displayed on the surface of the phage. Scientists have won a Nobel Prize for their work on phage display in the directed evolution of novel proteins, particularly the production of antibody-based drugs; AEBi does something similar with peptides that may have advantages over antibodies, including being smaller, cheaper and easier to produce and regulate.
Most anticancer drugs attack a specific target on or in the cancer cell, inhibiting it usually affecting a physiological pathway promoting cancer. However, mutations in downstream targets could render targets unrelated to the cancerous nature of the cell rendering the attacking drug ineffective. The simultaneous combination of several cancer targeting peptides for each cell and a potent peptide toxin that kills the cancer cells using at least three targeting peptides has made the treatment unaltered by the mutations; the cancer cells mutate so that the target receptors are abandoned by the cancer.
Instead of attacking one receptor, three are attacked at the same time, not even cancer can mutate three receptors at a time, Morad explains. The team relies on the toxin when the toxin is strong and the probability of destruction of the cancer cell is high before the detoxification can occur and the cell changes itself. Cytotoxic cancer therapy targets fast-growing cancer cells. However, cancer stem cells do not grow quickly and may escape treatment to regenerate again; according to the team, the multi-target attack ensures that they will all be destroyed.
The small size of the peptide parts of MuTaTo is able to sneak into places where others can not sneak behind the cancerous cancer shields, which should also make the entire molecule non-immunogenic in most cases and allow the repeated administration of it. The combination of several highly specific cancer-targeting peptides on a support for each cancer cell should increase specificity to the cancer cell.
The treatment will eventually be personalized, after a biopsy has been performed in the laboratory to badyze the overexpressed receptors, the patient will be given the exact badtail of molecules necessary for this patient's disease. Dr. Iian Morad suggests that their treatment could also reduce the nauseating side effects badociated with most cancer treatments.
It seems almost immediately that the P.R campaigns are beginning to discredit and discredit Israeli scientists. The American Cancer Society writes that their claims are unlikely, especially that their approach is not unique and that other similar approaches have failed. Israel's CEO, Advanced Technology Industries, says they have damaged the image of the life sciences sector in Israel. Dr. Ben Neel Director of the Perlmutter Cancer Center says "More likely, it is another claim in a long series of false, spurious, irresponsible and ultimately cruel promises." In addition to the concerns of external experts, the study was conducted only on mice and in vitro, as well as Dr. Robert Maki of the Northwell Health Cancer Institute, notes that there is no data available, on which AEBi claims to not have the necessary funding for publication. at the moment.
What works in animals does not always work in humans. and previous studies setting up roadblocks have failed because cancer cells have found their way around them. Cancer is indeed different from one person to another, but in theory it is promising. Why not let them finish their work and publish the results before destroying them. If they fail, so be it, this work will be taken into account by countless other promising people who have not kept their promises. For now, if funding for research is limited, what is the best use? Focus on research or fund publications; Advance research to find more targeting peptides and do more experiments, or write an article.
Cancer is a multi-billion dollar industry in the world that should be considered a parasite for humanity. Everything should be implemented to combat this cancer, including public education and the development of new drugs and therapies. So, why are they attacked, why is it so bad? they would not be the first to fail after suggesting a promise. Perhaps they should not have given a date or use such a strong wording, but this should be a welcome development, pending results. Only time will tell. We all want treatment.
Source link
